Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Orexigen Therapeutics Inc. Shares Have Seen the "Light"

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Orexigen Therapeutics (NASDAQ: OREX  ) , a clinical-stage biopharmaceutical company focused on developing therapies to treat obesity, soared as much as 30% after releasing the interim analysis of a safety study measuring the effect of its experimental chronic weight management drug, Contrave, on patients' cardiovascular health.

So what: According to the press release, Orexigen's Light Study, which included close to 10,000 patients, "clearly achieved the goal set by the FDA." Based on this news, Orexigen plans to resubmit its new drug application for Contrave (it's been rejected once before) within the next few weeks and could receive an approval as early as June 2014.

Now what: This is big news in many ways even if it doesn't appear like it on the surface. Orexigen's Contrave was rejected by the Food and Drug Administration originally in January 2011 due to cardiovascular safety concerns that necessitated this enormous study. This initial snippet of study data demonstrates that Contrave poses no increased heart attack risk concerns or adverse side effects, which should certainly give it some extra push for an FDA approval.

Another factor worth considering here is that it's light years (pardon the pun) ahead of its peers Arena Pharmaceuticals (NASDAQ: ARNA  ) with Belviq and VIVUS (NASDAQ: VVUS  ) with Qsymia with regard to a possible European approval. VIVUS' Qsiva (as it's known in the EU) was rejected on safety concerns while Arena pulled Belviq following an advisory meeting that suggested similar safety concerns. With Orexigen having already undertaken a large safety study, it could be sitting in the driver's seat for an EU approval as well.

Clearly, the big question now is whether the drug will sell. Qsymia sales struggled out of the gate, primarily as insurers were unwilling to cover the drug for a couple of months and consumers were unwilling to pay for it out of their own pocket. Arena's Belviq has seen a slightly quicker sales ramp-up than Qsymia, largely due to its perceived more-favorable safety profile and the fact that it has a large marketing partner in Eisai, but even its results have been unimpressive. We've definitely learned with this sector that approval plays second fiddle to a successful drug launch, but Orexigen may now have the upper hand.

Another company with an incredible growth opportunity on the horizon
Orexigen isn't the only company with an enormous opportunity on its doorstep. If you're looking for more great investing ideas then you should check out this incredible tech stock -- which is growing twice as fast as Google and Facebook, and more than three times as fast as and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!

Read/Post Comments (4) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 25, 2013, at 3:44 PM, marp11 wrote:

    light years hahaha good one

    BELVIQ with arna/ eisai and a 'partner'

    will be in europe before orex generic cocktail are BK

  • Report this Comment On November 25, 2013, at 3:45 PM, marp11 wrote:



    UP 58% IN 9 DAYS


  • Report this Comment On November 25, 2013, at 3:46 PM, marp11 wrote:

    thats now 5 new blogs today bashing arna

    think the shorts are panicked??

    wait a few more days

  • Report this Comment On November 26, 2013, at 9:18 AM, marp11 wrote:



Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2742263, ~/Articles/ArticleHandler.aspx, 9/28/2016 5:08:33 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
OREX $3.29 Up +0.05 +1.54%
Orexigen Therapeut… CAPS Rating: **
ARNA $1.77 Down -0.04 -2.21%
Arena Pharmaceutic… CAPS Rating: ***
VVUS $1.17 Down -0.03 -2.50%
VIVUS CAPS Rating: **